Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Keeps “Sector Perform” Rating at Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “sector perform” rating reiterated by Royal Bank Of Canada in a research note issued on Tuesday, Benzinga reports. They presently have a $737.00 target price on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target would indicate a potential downside of 2.03% from the stock’s previous close.

Other equities analysts have also issued research reports about the stock. Citigroup lifted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Guggenheim increased their price target on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research report on Thursday, July 9th. Sanford C. Bernstein upgraded Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. Finally, Leerink Partners upped their target price on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a research report on Monday, August 17th. Fourteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $802.18.

Regeneron Pharmaceuticals Stock Down 4.5%

REGN opened at $752.25 on Tuesday. Regeneron Pharmaceuticals has a 1 year low of $541.00 and a 1 year high of $859.34. The firm has a 50 day moving average price of $781.41 and a 200 day moving average price of $720.99. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The company has a market cap of $77.45 billion, a PE ratio of 18.59, a price-to-earnings-growth ratio of 1.54 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same period in the previous year, the company posted $12.81 earnings per share. Regeneron Pharmaceuticals’s revenue was up 16.7% compared to the same quarter last year. Sell-side analysts expect that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 31.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. The trade was a 1.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 4,146 shares of company stock worth $3,432,488. 6.97% of the stock is owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $5,682,636,000. State Street Corp boosted its holdings in shares of Regeneron Pharmaceuticals by 3.6% in the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after buying an additional 170,210 shares during the period. Franklin Resources Inc. grew its position in shares of Regeneron Pharmaceuticals by 4.4% during the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after buying an additional 106,861 shares during the last quarter. Nuveen LLC grew its position in shares of Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after buying an additional 835,240 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Regeneron Pharmaceuticals by 7.2% during the fourth quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company’s stock worth $1,228,127,000 after acquiring an additional 106,632 shares during the period. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.